G1 Therapeutics to Participate Virtually in the 2022 BTIG Biotechnology Conference and the 2022 Wedbush Pacgrow Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in August 2022.
- On Tuesday August 9, 2022, G1’s Chief Executive Officer Jack Bailey and other members of the executive team will participate in the virtual 2022 BTIG Biotechnology Conference. BTIG-hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.
- On Wednesday August 10, 2022, Jack Bailey and other members of the executive team will participate in the virtual 2022 Wedbush Pacgrow Healthcare Conference. Mr. Bailey will participate in a “Commercial Oncology” panel at 8:35AM ET. The webcast and replay of this event will be accessible on the of .
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit and follow us on Twitter @G1Therapeutics.
G1 Therapeutics™ and the G1 Therapeutics logo and COSELA® and the COSELA logo are trademarks of G1 Therapeutics, Inc.
Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
